# EDGAR Filing Document

**Accession Number:** 0001626644
**File Stem:** 0001683168-26-003682
**Filing Date:** 2026-5
**Character Count:** 7392
**Document Hash:** b650c2dc281f74dce268fd168148bb82
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-003682.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001683168-26-003682

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260506

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Odyssey Health, Inc.
- **CENTRAL INDEX KEY:** 0001626644
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 471022125
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56196
- **FILM NUMBER:** 26964411

**BUSINESS ADDRESS:**
- **STREET 1:** 2300 WEST SAHARA AVENUE
- **STREET 2:** SUITE 800-#4012
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89102
- **BUSINESS PHONE:** 702-780-6559

**MAIL ADDRESS:**
- **STREET 1:** 2300 WEST SAHARA AVENUE
- **STREET 2:** SUITE 800-#4012
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Odyssey Group International, Inc.
- **DATE OF NAME CHANGE:** 20141128

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: **May 6, 2026**

(Date of earliest event reported)

**<u>ODYSSEY HEALTH, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **<u>Nevada</u>** | **<u>000-56196</u>** | **<u>47-1022125</u>** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |

---

---

| | |
|:---|:---|
| **<u>2300 West Sahara Avenue, Suite 800 - #4012,<br> Las Vegas, NV</u>** | **<u>89102</u>** |
| (Address of principal executive offices) | (Zip Code) |

---

**<u>(702) 780-6559</u>**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |

---

**Securities registered pursuant to Section 12(g) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading Symbol** | **Name of Each Exchange on Which Registered** |
| Common Stock ($0.001 par value) | ODYY | OTC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 1.01.** | **Entry into a Material Definitive Agreement.** |

---

On May 6, 2026, Odyssey Health, Inc., a Nevada corporation (the "Company" "Odyssey"), received formal written notice from NeuRX Health, Inc. ("NeuRX"), a Wyoming corporation, advising that NeuRX is in breach of its contractual obligations with Davion Healthcare Plc ("Davion"), an Irish corporation, in connection with Davion's BreastCheck product. Specifically, NeuRX failed to obtain Davion's required approval prior to sublicensing the BreastCheck product to Odyssey. In addition, NeuRX breached the Representations and Warranties contained in the definitive agreement, under which NeuRX had expressly warranted to Odyssey that all necessary consents and approvals had been obtained. As a result, the notice stated that the definitive agreement between Odyssey and NeuRX, dated October 14, 2025, and which closed on April 21, 2026, is immediately cancelled.

The information set forth in this Form 8-K Current Report filed on May 11, 2026, is hereby incorporated by reference into this Form 8-K Current Report.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

**(d) Exhibits.**

<u>Exhibit No.</u> <u>Description</u> <br> 10.1 [NeuRX Health, Inc. Revocation Letter dated May 6, 2026.](odyssey_ex1001.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Odyssey Health, Inc.** | **Odyssey Health, Inc.** |
| Date: May 11, 2026 | By: | /s/ Joseph Michael Redmond |
|  |  | Joseph Michael Redmond<br> Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

---

| | |
|:---|:---|
| **NeuRX Health, Inc.** | **Tel: 401-225-6000** |

---

May 6, 2026

Revocation of Planned Sub-License Agreement

RE: NeuRX Health Inc. and Odyssey Health Inc.

Dear Mr. Redmond:

In the last few day, we were made aware of the fact that our licensing and royalty agreement(s) with Davion Healthcare Plc ("Davion"), related to their BreastCheck product, which includes global licenses for both the manufacturing and distribution, together with the marketing of BreastCheck, cannot be sub-licensed, reassigned to, or acquired by any other company, including change of our company name in any way shape or form, without express written consent of Davion.

We now acknowledge that we had no legal right to enter into any agreement with you, without the written approval of Davion. Davion has never given, and we have never asked for such approval, which was our error. Davion has advised us that had they been formally notified of the planned sublicense agreement, prior to us executing it with you, they would have declined to approve it.

As a result of our breach of contract with Davion, we regret to inform you that all such agreements, understandings, and efforts made between our two companies to appoint you as a Global Distributor/Manufacturer for BreastCheck are cancelled with immediate effect.

Davion has advised us that they would require you to announce with immediate effect your withdrawal of your previous public notifications that you hold a sub license for BreastCheck, so as not to mislead your shareholders and the market you are listed on and the one Davion is planning to join shortly.

Sincerely,

/s/ Robert Hainey

Robert Hainey

CEO

**24 Quaker Lane, Unit J, Warwick, RI 02886**